The global diabetic assays market encompasses a wide range of diagnostic tools and tests designed to assess and monitor diabetes-related parameters. These assays play a crucial role in understanding patients' glucose levels, insulin production, and overall metabolic health. The market includes various types of diagnostic assays such as blood glucose tests, HbA1c tests, oral glucose tolerance tests, and urine tests. These assays aid healthcare professionals’ inaccurate diabetes diagnosis, treatment monitoring, and risk assessment. The global diabetic assays market is integral to the broader healthcare sector's efforts to address the growing burden of diabetes on a global scale.
Access Full Report at https://www.databridgemarketresearch.com/reports/global-diabetic-assays-market
Data Bridge Market Research analyses that the Global Diabetic Assays Market is expected to grow at a CAGR of 4.50% in the forecast period of 2023 to 2030 and is expected to reach USD 4.6 billion by 2030 from USD 3.23 billion in 2022. The expanding aging demographic globally heightens diabetes susceptibility. With a rising elderly population, demand surges for diagnostic assays to effectively manage diabetes-related health issues, emphasizing the pivotal role of advanced diagnostic technologies in catering to the specific healthcare needs of aging individuals.
Key Findings of the Study
Growing awareness and education is expected to drive the market's growth rate
As diabetes awareness grows, individuals are increasingly opting for regular screenings, spurred by the recognition of diabetes and its potential complications. Globally, healthcare providers and governments underscore the critical significance of early detection and monitoring in diabetes management. This heightened awareness not only encourages proactive health measures but also amplifies the demand for advanced diabetic assays, reflecting a concerted effort to address diabetes at its earliest stages for improved patient outcomes.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015-2020)
|
|
Quantitative Units
|
Revenue in USD Billion, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Type (Assays, Devices, Consumables), Disease Type (Type 1 Diabetes, Type 2 Diabetes, Gestational Diabetes), Deployment (Automated, Manual), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Amgen Inc., Abbvie, Inc (U.S.), Novartis AG (Switzerland), Teva Pharmaceutical Industries Ltd (Israel), Pfizer Inc (U.S.), Merck & Co., Inc. (U.S.), Abbott (U.S.), Siemens Healthcare GmbH (Germany), Hologic, Inc. (U.S.), Dynatronics Corporation (U.S.), Biomerieux (France), Bio-Rad Laboratories, Inc. (U.S.), BioMarin (U.S.), Quotient Suisse SA (Switzerland), BAG Health Care GmbH (Germany), DiaSorin S.p.A (Italy), DRG INSTRUMENTS GMBH (Germany), PTS Diagnostics (U.S.), Ortho Clinical Diagnostics (U.S.), Diazyme Laboratories, Inc (U.S.), ETHOS BIOSCIENCES (U.S.), Abnova Corporation (Taiwan), Monobind Inc. (U.S.)
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis:
The global diabetic assays market is segmented on the basis of type, disease type, deployment, end-users, and distribution channel.
- On the basis of type, the global diabetic assays market is segmented into assays, devices, and consumables
- On the basis of disease type, the global diabetic assays market is segmented into type 1 diabetes, type 2 diabetes, and gestational diabetes
- On the basis of deployment, the global diabetic assays market is segmented into automated, and manual
- On the basis of end-users, the global diabetic assays market is segmented into hospitals, homecare, specialty clinics, and others
- On the basis of distribution channel, the global diabetic assays market is segmented into hospital pharmacy, online pharmacy, and retail pharmacy
Major Players
Data Bridge Market Research recognizes the following companies as the major global diabetic assays market players in global diabetic assays market are Quotient Suisse SA (Switzerland), BAG Health Care GmbH (Germany), DiaSorin S.p.A (Italy), DRG INSTRUMENTS GMBH (Germany), PTS Diagnostics (U.S.), Ortho Clinical Diagnostics (U.S.), Diazyme Laboratories, Inc (U.S.), ETHOS BIOSCIENCES (U.S.), Abnova Corporation (Taiwan), Monobind Inc. (U.S.)
Market Developments
- In 2019, Siemens Healthineers AG launched its extensive range of products and services at MedLab Middle East 2019 in its main areas of laboratory diagnostics and molecular medicine. MedLab is the only medical laboratory operation that provides vendors a chance to meet a varied audience of customers. More than 19,610 health labs and practitioners from manufacturers to senior end-users accepted the 2019 version in the search for the latest innovative products. With this exhibition, the company has displayed there products to spread its market global presence in field of in-vitro diagnostics
- In 2019, Abbott (U.S.) launched its first rapid point-of-care HbA1c test to diagnose diabetes “Afinion HbA1c Dx assay” for use on Afinion AS100 Analyzer and Afinion 2 Analyzer. The Afinion HbA1c Dx assay is the first and rapid point-of-care method approved by the U.S. FDA to support various healthcare professionals in the diagnosis and treatment of diabetes. This launch will enhance the product portfolio and user base of the company
Regional Analysis
Geographically, the countries covered in the global diabetic assays market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
As per Data Bridge Market Research analysis:
Asia-Pacific is the dominant region in the global diabetic assays market during the forecast period 2023-2030
Asia-Pacific dominates the global diabetic assays market due to its emerging economic conditions and heightened vendor investments. The region's robust economic growth fosters an environment conducive to the widespread development of diabetes assays. With vendors actively investing in research and innovation, Asia-Pacific stands at the forefront of advancements in diabetic diagnostics, reflecting a dynamic landscape driven by economic progress and a commitment to enhancing healthcare solutions for diabetes management.
North America is estimated to be the fastest-growing region in the global diabetic assays market for the forecast period 2023 -2030
North America is expected to dominate the global diabetic assays market, experiencing consistent growth due to the rising prevalence of diabetes in the U.S. population. The increasing incidence necessitates heightened detection through diabetic assays for the proactive identification and monitoring of diabetes. This positive trend underscores the critical role of advanced diagnostic tools in managing the escalating health challenges posed by diabetes in the North American region.
For more detailed information about the global diabetic assays market report, click here – https://www.databridgemarketresearch.com/reports/global-diabetic-assays-market
